Authors


Eileen Gamagami, PhD

Latest:

Long-Term Management of Patients with P53 Aberrations

Treatment approaches to address mutations or deletions of chromosome 17p are needed due to the surfacing of point mutations, including TP53 aberrations in chronic lymphocytic leukemia.


Andrew A. Lane, MD, PhD

Latest:

Multi-Stage Trial of Tagraxofusp Shows Frontline Efficacy in BPDCN

Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.


Sanjay K. Juneja, MD

Latest:

Juneja Reflects on Becoming a Targeted Oncology 2024 Oncology Icon

Sanjay K. Juneja, MD, delves into what being recognized as an oncology icon for Targeted Oncology means to him.


Mwanasha Merrill

Latest:

PD-1 Blockade and Transplant as a Potential New Treatment in PTCL

Mwanasha Merrill discusses results from a phase 2 study which evaluated PD-1 blockade post autologous stem cell transplantation with pembrolizumab in patients with peripheral T-cell lymphoma.


Brendon Stiles, MD

Latest:

Exploring the Importance of Finding a Molecular Target in Lung Cancer

Brendon Stiles, MD, discusses the current landscape for treating patients with metastatic lung cancer.


Jens Hillengass, MD, PhD

Latest:

Key Takeaways on Recent Data in Multiple Myeloma from ASH 2023

Following their review of clinical trial data presented at ASH 2023, the Oncology Brothers offer their key takeaways on recent updates in multiple myeloma.


Sandra Toogood, BPharm

Latest:

Liquid Biopsy Holds Promise in Prostate Cancer Diagnosis

According to Joshua M. Lang, MD, MS, the importance of molecular understanding, especially in initially focusing on the genetics of PCa and how that can inform new therapies, has been one of the revolutions in PCa.


Crystal Ritchey, PhD

Latest:

Risk-Based Treatment of Hodgkin Lymphoma in the Era of Novel Therapies

Despite complete remission rates of up to 90%, late toxicities, such as secondary malignancies and cardiovascular events, are key concerns in patients treated for early-stage Hodgkin lymphoma.


Amir Khan, MD

Latest:

Study Investigators Question the Rise of CRC in Young Adult Patients

Amir Khan, MD, discusses the possible reasons for the rising incidence of young adult patients with gastric cancer and colorectal cancer at the 2020 Gastrointestinal Cancers Symposium.


Bhavana Pothuri, MD

Latest:

Unmet Needs in Patients With Recurrent and dMMR Endometrial Cancer

Bhavana Pothuri, MD, discusses the biggest unmet needs for patients with endometrial cancer.



Hannah Clarke

Latest:

Enfortumab Vedotin With Pembro Improves Survival, Maintains QOL in Urothelial Cancer

A study found that enfortumab vedotin with pembrolizumab significantly improves survival and maintains quality-of-life compared with chemotherapy for locally advanced or metastatic urothelial cancer.


Thomas Habermann, MD

Latest:

Polatuzumab Vedotin Plus R-CHOP May Improve Outcomes For DLBCL Patients

Thomas Habermann, MD, discusses R-CHOP and how it can be improved upon as a treatment method for diffuse large B-cell lymphoma.


Lucy Gilbert, MD, MSc

Latest:

Mirvetuximab Soravtansine Combination Improves Responses in Platinum-Agnostic Ovarian Cancer

Lucy Gilbert, MD, MSc, discusses the findings from a phase 1b trial in which mirvetuximab soravtansine was combined with bevacizumab in recurrent, high-grade epithelial ovarian cancer regardless of platinum sensitivity.



Jaime Merchan, MD

Latest:

Merchan’s Takeaways From the CLEAR Study in Advanced RCC

Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from the phase 3 CLEAR study in advanced renal cell carcinoma (RCC).


Sairah Ahmed, MD

Latest:

Research Ongoing for CAR T-Cell Therapy Axi-Cel in Lymphoma

Sairah Ahmed, MD, discusses the continued investigations of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy used in multiple types of lymphoma.


Asutosh Gor, MD

Latest:

Building a Patient-Centered Ecosystem Leads to Better Care

Within the past decade, there has been a surge in terms such as value-based care, patient-centered care, shared decision-making, and more at the macro level of health care delivery in the US.


Anita Kumar, MD

Latest:

What Is High-Risk Mantle Cell Lymphoma, and How Should We Treat It?

Improving patient prognostication in mantle cell lymphoma informs treatment decisions and enhances our understanding of the disease's biology.


Nirav N. Shah, MD

Latest:

Pirtobrutinib Produces Durable Responses in Pretreated MCL

Nirav Shah, MD, discusses long-term data from the phase 1/2 BRUIN study which evaluated pirtobrutinib in mantle cell lymphoma, and next steps for evaluating the agent.


Paula Rodriguez-Otero, MD, PhD

Latest:

Behind the FDA Approval of Daratumumab Plus VRd in Newly Diganosed Myeloma

Paula Rodríguez Otero, MD, PhD, discussed the findings from the minimal residual disease analysis of the PERSEUS study.


Tanya Gupta, MD

Latest:

Gupta Explores Sacituzumab Govitecan in Advanced Breast Cancer Treatment

Following discussions on ado-trastuzumab emtansine and fam-trastuzumab deruxtecan-nxki, Tanya Gupta, MD, discusses sacituzumab govitecan and its approval from the FDA in the breast cancer space.


Igor Astsaturov, MD, PhD

Latest:

Astsaturov on the Phase 1 Study of LP-184 in Advanced Solid Tumors

Igor Astsaturov, MD, PhD, discusses the planned phase 1 trial of LP-184 in multiple advanced solid tumors and central nervous system cancers, including pancreatic cancer.


Yann-Alexandre Vano, MD

Latest:

Vano Highlights Trials and Data in RCC

Yann-Alexandre Vano, MD, discusses some of the exciting data being seen in the renal cell carcinoma space.


Sophia Kamran, MD

Latest:

Anticipating Expanded Uses of Radiotherapy in Urothelial Carcinoma

Sophia Kamran, MD, discusses future roles that radiation oncology will play in combination with resection and targeted therapy in urothelial carcinoma.


Jane Mendez, MD, PhD

Latest:

Challenges of Breast Cancer in Young Adults

According to Jane Méndez, M.D., FACS, special considerations come into play when diagnosing and treating young adults with breast cancer.


Leora Horn, MD, MSc

Latest:

NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over Chemotherapy

Leora Horn, MD, MSc, discusses the data accrued from Flatiron and from a phase 1/2 trial of patients with refractory non–small cell lung cancer with EGFR exon 20 insertions receiving mobocertinib compared with currently approved therapies.



Catherine J. Lee, MD, MS

Latest:

Severe, Multi-Organ Chronic Graft-versus- Host Disease (cGvHD): Diagnosis and Initial Treatment Approach

This segment covers the diagnosis and initial treatment of a case of severe, multi-organ cGvHD, including the use of high-dose corticosteroids and other systemic agents.


Vincent Law

Latest:

New Method Unlocks Treatment for Melanoma's Brain Invasion

Vincent Law, research associate at Moffitt Cancer Center, discusses the key takeaways and implications of this research.